J. Goldman & Co’s Syndax Pharmaceuticals SNDX Stock Holding History

J. Goldman & Co’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-39,538	Closed	-$563K	–	450
2018 Q1	$563K	Sell	39,538 -31,462	-44%	-$334K	0.02%	278
2017 Q4	$622K	Buy	71,000 +19,000	+37%	+$188K	0.03%	258
2017 Q3	$608K	Sell	52,000 -95,181	-65%	-$1.17M	0.03%	263
2017 Q2	$2.06M	Buy	+147,181	New	+$1.68M	0.11%	178

Other funds holding SNDX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

J. Goldman & Co's SNDX Position: Q2 2018 in Review

J. Goldman & Co sold out of Syndax Pharmaceuticals (SNDX) in Q2 2018, closing a stake of 39,538 shares — an estimated $563K sold.

J. Goldman & Co first reported a position in SNDX in Q2 2017 and held it in 4 quarters. The position peaked at $2.06M in Q2 2017. 84 funds tracked by Wall St. Rank hold SNDX as of Q2 2018.

J. Goldman & Co reported no remaining Syndax Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
J. Goldman & Co sold 39,538 Syndax Pharmaceuticals shares in Q2 2018, an estimated $563K.
J. Goldman & Co first reported a position in Syndax Pharmaceuticals in Q2 2017 and held it in 4 quarters.
J. Goldman & Co's Syndax Pharmaceuticals position peaked at $2.06M in Q2 2017.
84 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2018.

Based on J. Goldman & Co's 13F filing for Q2 2018, filed 14 Aug 2018.